Last reviewed 2026-04-23 · How we verify

VFEND® I.V., Oral

VFEND® I.V., Oral is an antifungal medication that inhibits the synthesis of ergosterol, an essential component of fungal cell membranes.

VFEND® I.V., Oral is an antifungal medication that inhibits the synthesis of ergosterol, an essential component of fungal cell membranes. Used for Treatment of invasive aspergillosis, invasive candidiasis, and esophageal candidiasis.

At a glance

Mechanism of action

VFEND® I.V., Oral works by targeting the enzyme lanosterol 14α-demethylase, which is necessary for the conversion of lanosterol to ergosterol. This inhibition disrupts the integrity of the fungal cell membrane, ultimately leading to cell death. As a result, VFEND® I.V., Oral is effective against a wide range of fungal infections.

Approved indications

• Treatment of invasive aspergillosis, invasive candidiasis, and esophageal candidiasis

Common side effects

• Headache
• Nausea
• Vomiting
• Diarrhea
• Abdominal pain

Key clinical trials

• A Clinical Study Intended To Compare Treatment With Voriconazole To Treatment With Amphotericin Followed By Fluconazole In Patients With Candidemia, A Serious Fungus Infection Of The Blood. (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.